~~<i id='42AB080B1A'><strike id='42AB080B1A'><tt id='42AB080B1A'><pre id='42AB080B1A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：explore 2025-08-27 16:47:58 - browse：56822

Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT — Adobe

For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

But don’t take their numbers as gospel, experts warned.

“It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Wikipedia

hotspot

focus

explore

hotspot

explore

AdobeWASHINGTON—WuXiBiologicsexecutiveshavejoinedthelobbyingfrayinthelead-uptoamovebyCongresstoaddth

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Hottest summer in 2,000 years puts focus on extreme heat, health

PBM reform efforts get punted in Congress

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

focus

comprehensive

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why palliative psychiatry is worth discussing

ChatGPT in medicine: STAT answers readers' burning questions

A new nitrogen execution bill also undermines medical licensing

As demand for Covid shots wanes, Moderna seeks its next success

He's a Nobel laureate. Critics say he was misleading on Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Sports medicine is finally prioritizing gender equality

Free medical tuition alone isn't enough to close gaps in primary care

hotspot

Medicare inequities exacerbate Puerto Rico’s health disparities

What a koala virus tells us about the human genome

Oak Street deal isn't the answer to health care's woes

What a koala virus tells us about the human genome

6 phony surgeries that take placebo to the extreme

STAT series 'Denied by AI' wins major journalism prizes

focus

explore

hotspot

explore